Authors
Latest:
Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCLJean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.
Latest:
Dr. Lopategui on the Evolution of Targeted Therapies in NSCLCJean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.
Latest:
Dr. Machiels on Challenges and Ongoing Trials in Head and Neck CancerJean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses challenges still facing the field of head and neck cancer and ongoing trials with a goal to improve patient outcomes.
Latest:
Dr. Wright on the Benefit of Moderate Hypofractionation in Early-Stage Breast CancerJean Wright, MD, discusses the benefit of moderate hypofractionation in patients for adjuvant radiotherapy in patients with early-stage breast cancer.
Latest:
Dr. Blay on Treatment Considerations in Soft Tissue SarcomasJean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.
Latest:
Jeanine Stiles on the Importance of Supportive Care for Patients With CancerJeanine Stiles, chief administrative officer, associate director for administration, UC Davis Comprehensive Cancer Center, discusses the importance of supportive care for patients with cancer.
Latest:
Myeloproliferative Neoplasm Management: Future Directions in CareClosing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
Latest:
New Therapies for Prostate Cancer: The PracticalitiesNow, with four new agents approved in the last two years and two promising agents in the pipeline, therapy selection and potential outcomes are changing.
Latest:
Dr. Chern on Challenges Regarding Germline Testing in Ovarian CancerJeannie Chern, MD, discusses challenges with germline molecular testing for patients with ovarian cancer.
Latest:
Jeannine Brant on the Benefits of Patient-Reported OutcomesJeannine Brant, PhD, Billings Clinic, discusses the benefits of patient-reported outcomes in cancer care.
Latest:
Dr. Katzel on Differences in Therapy Between Men and Women With Head and Neck CancerJed A. Katzel, MD, Hematology, Kaiser Permanente Santa Clara Medical Center, discusses differences in treatment decisions between men and women with head and neck cancer.
Latest:
Dr. Katzel on Women Being Undertreated for Head and Neck CancerJed Katzel, MD, Hematology, Kaiser Permanente Santa Clara Medical Center, discusses research presented at the 2018 ASCO Annual Meeting, which evaluated whether women are undertreated for head and neck cancer.
Latest:
Dr. Wolchok on Weighing Risk and Benefit of Nivolumab/Ipilimumab Combo in MelanomaJedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses weighing the overall survival (OS) benefit with the increased risk of toxicities seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma.
Latest:
Dr. Geschwind on Locoregional Therapy for Patients With Liver CancerJeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).
Latest:
Dr. Michalski on Minimizing Long-Term Consequences of RadiationJeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.
Latest:
Dr. Sharman on the Challenges of Adjusting Treatment Based on MRD Status in CLLJeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.
Latest:
TechSectors: Mobile/Wireless: iPhone 3G, the First 30 DaysLast year, I promised myself not to accept waiting in line for the iPhone "classic" and was fortunate enough to sneak into an Apple store late one night to purchase one without any hassles.
Latest:
Dr. Sharman on 5-Year Data From the Elevate CLL TN Trial in CLLJeff Sharman, MD, discusses 5-year follow-up data from the phase 3 Elevate CLL TN trial in treatment-naïve patients with chronic lymphocytic leukemia.
Latest:
Dr. Yorio on the Safety of Targeted Therapies in BRAF-Mutated MelanomaJeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.
Latest:
Dr. Weber on the Toxicities Associated With Immunotherapy in Lung CancerJeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.
Latest:
Dr. Sosman on the Mechanism of Action of IpilimumabJeffrey A. Sosman, MD, professor of medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, describes the mechanism of action of ipilimumab in patients with melanoma.
Latest:
Dr Crawford on the Evolving Role of Active Surveillance in Prostate CancerE. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.
